Research conducted at Center for Biologics Evaluation and Research has updated our knowledge about vaccinia virus
2007 OCT 29 -- Researchers detail in 'Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity,' new data in vaccinia virus. "'The smallpox vaccine Dryvax, which consists of replication-competent vaccinia virus, elicits antibodies that play a major role in protection. Several vaccinia proteins generate neutralizing antibodies, but their importance for protection is unknown," scientists in the United States report. "We investigated the potency of antibodies to the A27 protein of the mature virion in neutralization and protection experiments and the contributions of A27 antibodies to Dryvax-induced immunity. Using a recombinant A27 protein (rA27), we confirmed that A27 contains neutralizing determinants and that vaccinia immune globulin (VIG) derived from Dryvax recipients contains reactivity to A27. However, VIG neutralization was not significantly reduced when A27 antibodies were removed, and antibodies elicited by an rA27 enhanced the protection conferred by VIG in passive transfer experiments," wrote Y. He and colleagues, Center for Biologics Evaluation and Research. The researchers concluded: "These findings demonstrate that A27 antibodies do not represent the major fraction of neutralizing activity in VIG and suggest that immunity may be augmented by vaccines and immune globulins that include strong antibody responses to A27." He and colleagues published their study in the Journal of Infectious Diseases (Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity. Journal of Infectious Diseases, 2007;196(7):1026-32). For more information, contact Y. He, Center for Biologics Evaluation and Research, Division of Viral Products, US Food and Drug Administration, Bethesda, MD USA.. Publisher contact information for the Journal of Infectious Diseases is: University Chicago Press, 1427 E 60th St., Chicago, IL 60637-2954, USA. Keywords: United States, Bethesda, Biologics, Biotechnology, Vaccines, Vaccinia Virus, Viral Research, Virology. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
